REG - Spirax Group PLC - Trading Update

SpiraxAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM2908Ha&default-theme=true

RNS Number : 2908H  Spirax Group PLC  13 November 2025

13 November 2025

Trading update in respect of the four months ended 31 October 2025

Group organic revenue growth and margin ahead of H1; reiterating full year
outlook

 

Economic environment

Global IP(1) (excluding China) for the first nine months of the year was 1.6%
and full year forecasts have been revised down to 1.6%.  Third quarter IP was
lower than the first half with continued weakness in key markets such as the
USA, Germany, France, Italy and the UK.  Uncertainty around the broader
impact of tariffs on global trade has persisted and continues to dampen
business confidence and demand for large projects.

Trading

We have continued to focus on the strategic priorities within our control to
drive growth and margin.  As a result, both Group organic sales growth and
adjusted operating profit margin for the ten months ended 31 October were
ahead of organic growth and margin in the first half.

Steam Thermal Solutions (STS) sales for the four months to October were
broadly level organically on the prior year as large project sales continue to
be impacted by the challenging IP conditions.  Excluding large project sales
in China and Korea, STS sales were ahead of the prior year.  As expected, the
rate of organic sales decline in China is moderating compared to the first
half, with continuing double-digit growth in MRO sales.  Organic sales growth
in Korea is also recovering, with both orders and sales expected to grow in
the second half.

In Electric Thermal Solutions, the strong organic sales growth of the first
half continued in the four months to October.  Process Heating continued to
benefit from ongoing operational improvements driving increased shipments from
our order book, including residual legacy orders.  Organic sales growth in
Equipment Heating was supported by continuing strength in demand for our
Semicon equipment solutions.

In Watson-Marlow, double-digit order growth in Biopharm has continued into the
second half and, as expected, this has driven an acceleration in sales growth
during the four months to October compared to the first half.  Process
Industries sales also grew strongly and above the rate of growth in the first
half, supporting strong overall organic sales growth in Watson-Marlow.

We remain on track to deliver annualised savings of approximately £35 million
from our restructuring, most of which are being reinvested in our organic
growth priorities.  The associated costs remain in line with our expectations
and are expected to be mostly incurred in 2025.

Financial position

Net borrowings (excluding leases) at 31 October were £596 million (30 June:
£658 million), with the Group net debt to EBITDA ratio at 1.6x (30 June:
1.8x).

Outlook

Our Group guidance for the full year remains unchanged. We continue to
anticipate organic growth in Group revenues consistent with that achieved in
2024 and well ahead of IP.  Group adjusted operating profit margin is
expected to be ahead of the currency adjusted 2024 margin, driving mid-single
digit organic growth in adjusted operating profit.

(1) Global Industrial Production growth (source: CHR Economics)

 Further information:
 Louisa Burdett, Chief Financial Officer  +44 (0) 1242 240281
 Mal Patel, Head of Investor Relations    +44 (0) 1242 240281

 Media:
 Martin Robinson, Teneo                   +44 (0) 20 7260 2700

 

About Spirax Group plc

Spirax Group is positioned to play a critical role in enabling the industrial
transition to net zero, aligned to our Purpose to create sustainable value for
all our stakeholders as we engineer a more efficient, safer and sustainable
world.  We put solving customers' problems at the heart of our total
solutions approach.  Our global thermal energy and fluid technology solutions
improve operating efficiency and safety in our customers' critical industrial
processes.  Our new-to-world decarbonisation* solutions will use our
proprietary technologies to electrify boilers, for the raising of steam, as
well as the electrification of other critical industrial process heating
applications.

Spirax Group comprises three strong and aligned Businesses: Steam Thermal
Solutions helps customers control and manage steam within their mission
critical industrial applications, such as cleaning, sterilising, cooking and
heating.  We are helping to put food safely on the world's tables and keeping
our hospitals running. Electric Thermal Solutions has proprietary technologies
that deliver electrification solutions at scale in industrial settings,
including for the raising of steam, supporting our customers to achieve their
net zero goals. We also deliver freeze protection and defrost solutions
critical to aviation and space industries and ensure thermal uniformity in
Semiconductor chip manufacturing to power the critical electronic systems we
rely on.  Watson‐Marlow Fluid Technology Solutions is engineering vital
fluid technology solutions that optimise the efficient use of resources and
support advancements in global health, such as lifesaving vaccines and gene
therapies.

Spirax Group is headquartered in Cheltenham (UK). We have over 30
strategically located manufacturing plants around the world and are committed
to creating a safe and inclusive working culture for our 10,000 colleagues,
operating in nearly 70 countries and serving over 100,000 customers
globally.

The Company's shares have been listed on the London Stock Exchange since 1959
(symbol: SPX) and we are a constituent of the FTSE 100 and the FTSE4Good
Indexes.

 

* Eliminates Scopes 1 and 2 greenhouse gas emissions when connected to a green
electricity source.

 

Further information can be found at spiraxgroup.com
(http://www.spiraxsarcoengineering.com)

 

RNS filter: Results

LEI 213800WFVZQMHOZP2W17

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBTBITMTMBBPA



            Copyright 2019 Regulatory News Service, all rights reserved